Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05778695 · ClinicalTrials.gov registry record · NA
Brain Small Chain Fatty Acid Metabolism in Parkinson Disease: Ketones
A NA study, sponsored by University of Michigan.
- Terminated
- Registry status
- NA
- Development phase
- 16
- Enrollment target
NCT05778695: Clinical Trial NA study, sponsored by University of Michigan.
NCT05778695 is a NA study that was terminated before completion, run by University of Michigan. The registered enrollment target is 16 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05778695, a NA study, was terminated before completion, sponsored by University of Michigan.
- TERMINATED
- Registry status
- NA
- Development phase
- 16 participants
- Enrollment target
Study Summary
Small exploratory open-label pilot study to assess supplementation of a ketone ester (KetoneAid) as a potential therapy for persons with Parkinson disease (PD), Parkinson Disease Dementia/Lewy Body Dementia (PDD/LBD), and healthy controls.
Primary Outcome
Continuous glucose meter 7-10-day average glucose readings before/after open-label treatment with the ketone ester in patients with PD, Parkinson's disease dementia/Lewy body dementia, and normal controls. Healthy fasting blood glucose ranges from 70 to 99 milligrams per deciliter (mg/dL), with a healthy maximum of 180 mg/dL within 2 hours of eating meals.
Interventions
- DIETARY_SUPPLEMENT Ketone Ester (R)-3-Hydroxybutyl (R)-3-Hydroxybutyrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2023-03-09 |
| Est. Completion | 2023-10-04 |
| Phase | NA |
Why NCT05778695 stopped before completion
NCT05778695 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Ketone Ester (R)-3-Hydroxybutyl (R)-3-Hydroxybutyrate is the first listed.
NCT05778695 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05778695 about?
NCT05778695 is a clinical study titled "Brain Small Chain Fatty Acid Metabolism in Parkinson Disease: Ketones". Small exploratory open-label pilot study to assess supplementation of a ketone ester (KetoneAid) as a potential therapy for persons with Parkinson disease (PD), Parkinson Disease Dementia/Lewy Body Dementia (PDD/LBD), and healthy controls.
What is the current status of trial NCT05778695?
This trial is currently terminated. It is a NA study. The enrollment target is 16 participants. The study started on 2023-03-09. Estimated completion is 2023-10-04.
What interventions are being tested in trial NCT05778695?
The interventions under investigation include: Ketone Ester (R)-3-Hydroxybutyl (R)-3-Hydroxybutyrate (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05778695?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05778695's enrollment target sits among peer trials
16 1871st of 2000 higher than 120 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI